AccessibilityHelpAbout Us
N4 Pharma Plc logo

N4 Pharma Plc(LSE) N4P

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-91%
5 Year-93%
1 Year+14%
1 Month-11%
N/A
N4 Pharma Plc last closing stock price
MetricPriceDate
Last closeGBX 0.602026-09-11
N4 Pharma Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4%GBX 0.632026-09-04
1 month-11.11%GBX 0.682026-08-12
3 month+4.35%GBX 0.582026-06-12
Year to date+14.29%GBX 0.532025-12-31
1 year+14.29%GBX 0.532025-09-11
3 year-55.56%GBX 1.352023-09-12
5 year-92.94%GBX 8.502021-09-10
Since inception-91.37%GBX 0.062017-05-03

N4 Pharma Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£12.93K

Net Income (TTM)

-£2.18M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 24, 2026

N4P News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About N4 Pharma Plc

N4 Pharma Plc is a specialized pharmaceutical company focused on developing advanced silica nanoparticle delivery platforms for the pharmaceutical and biotechnology sectors in the UK. The company's flagship product, Nuvec, is a non-viral adjuvant delivery system aimed at enhancing vaccine development and cancer therapies.

Products and Services
  • Nuvec: A cutting-edge delivery system for vaccines and cancer therapies
  • Research and development services for pharmaceutical companies
  • Collaborative partnerships with biotech organizations
Growth Outlook
  • Strong focus on innovative drug delivery systems positions the company for future growth
  • Increasing demand for effective vaccine delivery solutions in the healthcare sector
  • Potential for strategic partnerships to expand market reach and capabilities
Financial Highlights
  • Recent quarterly revenue of 3,690 GBP, showing a steady demand for products
  • Cash and cash equivalents of 1,727,543 GBP, providing operational stability
  • Current ratio of 11.93 indicates strong liquidity and financial health
N4 Pharma Plc operates in the healthcare sector, specifically within the drug manufacturing industry, and is headquartered in London. The company has a small team of five employees, reflecting its focused approach to innovation and development. Despite recent financial challenges, including net losses, the company maintains a robust cash position, which supports ongoing research and development efforts. The current ratio suggests that N4 Pharma is well-positioned to meet its short-term obligations, providing a cushion as it navigates the complexities of the pharmaceutical landscape. The emphasis on advanced delivery systems aligns with industry trends, potentially leading to significant growth opportunities in the future.
AI Generated • Sep 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Nigel James Theobald

Website

www.n4pharma.com

Headquarters

London, EC3V 0HR, GB

N4P Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

-15199.56%

Net Income Margin

-16589.87%

Return on Equity

-84.97%

Return on Capital

-188.53%

Return on Assets

-103.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

£9.24K

Operating Income

-£2.41M

EBITDA

-£2.47M

Operating Cash Flow

-£2.04M

Capital Expenditure

-£3.00

Free Cash Flow

-£2.04M

Cash & ST Invst.

£1.73M

Total Debt

£0.00

N4 Pharma Plc Performance Analysis

N4 Pharma Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 1,953N/A
20242024-12-31GBP 7,282272.9%
20252025-12-31GBP 7,264-0.2%
N4 Pharma Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31N/A
Q22024-06-30100.0%
Q42024-12-31-13.6%
Q22025-06-309.3%
N4 Pharma Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.01-35.3%
20232023-12-31GBP -0.01-5.5%
20242024-12-31GBP -0.00-40.4%
20252025-12-31GBP -0.00-45.2%
N4 Pharma Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3110.7%
Q22024-06-3036.0%
Q42024-12-31-12.5%
Q22025-06-3050.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£3.69K

N/A

Gross Profit

£0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

5

N/A

Net Income

-£498.55K

+22.8%

EBITDA

-£470.22K

+27.2%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£1.73M

+33.9%

Total Debt

£0.00

N/A

Accounts Receivable

£118.11K

-43.6%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-1.03%

N/A

Return on Invested Capital

-1.03%

N/A

Free Cash Flow

-£444.37K

+28.9%

Operating Cash Flow

-£444.37K

+28.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CHLL.LChill Brands Group PLC
£0.02+0.00%
PRM.LProteome Sciences plc
£0.02+9.23%
TCF.LTheracryf Plc
£0.00-8.11%
CRTX.LCRISM Therapeutics Corporation
£0.11-0.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
ACVAACV Auctions
$10.43+0.44%
TNONTenon Medical
$7.19+0.36%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.63+0.06%
ORCLOracle
$156.35+0.02%

Questions About N4P

What is the current price of N4 Pharma Plc?

N4 Pharma Plc is trading at N/A per share.

What is the 52-week range for N4 Pharma Plc?

Over the past 52 weeks, N4 Pharma Plc has traded between N/A and N/A.

How much debt does N4 Pharma Plc have?

As of the most recent reporting period, N4 Pharma Plc reported total debt of £0.00.

How much cash does N4 Pharma Plc have on hand?

N4 Pharma Plc reported £1.08M in cash and cash equivalents in its most recent financial results.

What is N4 Pharma Plc’s dividend yield?

N4 Pharma Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services